|
Cardiomyopathy, Dilated
|
0.320 |
GeneticVariation
|
group |
BEFREE |
CAP2 mutation leads to impaired actin dynamics and associates with supraventricular tachycardia and dilated cardiomyopathy.
|
30518548 |
2019 |
|
Cerebrovascular accident
|
0.020 |
GeneticVariation
|
group |
BEFREE |
Hemorrhagic stroke was significantly less than ischemic stroke (0.17 per 100 patient-years in CAP and 0.09 per 100 patient-years in CAP2), and total stroke rates were significantly less than predicted by CHA<sub>2</sub>DS<sub>2</sub>-VASc score (78% reduction with CAP, 69% reduction with CAP2).
|
31806131 |
2019 |
|
Cardiomyopathy, Familial Idiopathic
|
0.020 |
GeneticVariation
|
disease |
BEFREE |
This is the first report of a recessive deleterious mutation in CAP2 and its association with DCM in humans.
|
30518548 |
2019 |
|
Bipolar Disorder
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
A linkage and exome study implicates rare variants of KANK4 and CAP2 in bipolar disorder in a multiplex family.
|
31400178 |
2020 |
|
Supraventricular tachycardia
|
0.010 |
GeneticVariation
|
disease |
BEFREE |
CAP2 mutation leads to impaired actin dynamics and associates with supraventricular tachycardia and dilated cardiomyopathy.
|
30518548 |
2019 |
|
Liver carcinoma
|
0.330 |
Biomarker
|
disease |
BEFREE |
These genes not only include known HCC-relevant genes such as MT1X, BMI1, and CAP2, but also include cancer genes that were not found previously to be closely related to HCC, such as TACSTD2.
|
25247452 |
2015 |
|
Liver carcinoma
|
0.330 |
Biomarker
|
disease |
CTD_human |
Computational Discovery of Niclosamide Ethanolamine, a Repurposed Drug Candidate That Reduces Growth of Hepatocellular Carcinoma Cells In Vitro and in Mice by Inhibiting Cell Division Cycle 37 Signaling.
|
28284560 |
2017 |
|
Cardiomyopathy, Dilated
|
0.320 |
Biomarker
|
group |
HPO |
|
|
|
|
Cardiomyopathy, Dilated
|
0.320 |
Biomarker
|
group |
BEFREE |
Targeting MRTF/SRF in CAP2-dependent dilated cardiomyopathy delays disease onset.
|
30762586 |
2019 |
|
Cardiomyopathy, Dilated
|
0.320 |
Biomarker
|
group |
MGD |
|
|
|
|
Myopathy
|
0.110 |
Biomarker
|
group |
HPO |
|
|
|
|
Myopathy
|
0.110 |
Biomarker
|
group |
BEFREE |
Cofilin2, a putative CAP2 interaction partner, has been recently implicated in myofibril actin cytoskeleton differentiation, and the myopathies in cofilin2 and CAP2 mutant mice showed striking similarities.
|
30962377 |
2019 |
|
Sensorineural Hearing Loss (disorder)
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
|
Lipodystrophy
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
|
Creatine phosphokinase serum increased
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Neutrophil abnormality
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Electromyogram abnormal
|
0.100 |
Biomarker
|
phenotype |
HPO |
|
|
|
|
Lipoatrophy
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
|
Keratoderma, Palmoplantar
|
0.100 |
Biomarker
|
disease |
HPO |
|
|
|
|
Cerebrovascular accident
|
0.020 |
Biomarker
|
group |
BEFREE |
Patients from the PROTECT-AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients With Atrial Fibrillation), PREVAIL (Watchman LAA Closure Device in Patients With Atrial Fibrillation Versus Long Term Warfarin Therapy), CAP (Continued Access to PROTECT-AF), CAP2 (Continued Access to PREVAIL), ASAP (ASA Plavix Feasibility Study With Watchman Left Atrial Appendage Closure Technology), and EWOLUTION (Registry on WATCHMAN Outcomes in Real-Life Utilization) trials receiving either OAC or APT post-implantation were matched and compared for nonprocedural bleeding and stroke or systemic thromboembolism over 6 months following implantation.
|
31171282 |
2019 |
|
Cardiomyopathy, Familial Idiopathic
|
0.020 |
Biomarker
|
disease |
BEFREE |
Mutations in the actin binding protein CAP2 can cause DCM and KO mice, either whole body (CAP2-KO) or cardiomyocyte-specific KOs (CAP2-CKO) develop DCM with cardiac conduction disease.
|
30762586 |
2019 |
|
Atrial Fibrillation
|
0.010 |
Biomarker
|
disease |
BEFREE |
We studied the device arms of 4 prospective Food and Drug Administration trials: PROTECT-AF (Watchman Left Atrial Appendage System for Embolic Protection in Patients With Atrial Fibrillation) (n=463); PREVAIL (Evaluation of the Watchman LAA Closure Device in Patients With Atrial Fibrillation Versus Long Term Warfarin Therapy) (n=269); CAP (Continued Access to PROTECT AF registry) (n=566); and CAP2 (Continued Access to PREVAIL registry) (n=578).
|
29752398 |
2018 |
|
Borderline Personality Disorder
|
0.010 |
Biomarker
|
disease |
BEFREE |
Our studysuggests involvement of KANK4 or CAP2 or both in BPD in this family.
|
31400178 |
2020 |
|
Bronchopulmonary Dysplasia
|
0.010 |
Biomarker
|
disease |
BEFREE |
Our studysuggests involvement of KANK4 or CAP2 or both in BPD in this family.
|
31400178 |
2020 |
|
Malignant Neoplasms
|
0.010 |
Biomarker
|
group |
BEFREE |
CAP2 may serve as a prognostic indicator for patients with gastic cancer.
|
30047046 |
2018 |